Aligos Therapeutics (ALGS) announced that the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option ...

Equities research analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for shares of Aligos Therapeutics in a report issued on Tuesday, March 11th. HC Wainwright analyst E.

H.C. Wainwright lowered the firm’s price target on Aligos Therapeutics (ALGS) to $70 from $75 and keeps a Buy rating on the shares. The firm is ...

Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) had its price objective cut by equities research analysts at HC Wainwright from $75.00 to $70.00 in a research note issued on Tuesday,Benzinga ...

SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes ...

S OUTH SAN FRANCISCO - Aligos Therapeutics, Inc. (NASDAQ:ALGS), a company specializing in therapies for liver and viral diseases with a current market capitalization of $96.58 million, announced ...

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best ...

Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $3.41 per share versus the Zacks Consensus Estimate of a loss of $1.91. This compares to loss of $5.50 per share a year ago.

ALIGOS THERAPEUTICS ($ALGS) is expected to release its quarterly earnings data on Monday, March 10th before market open, per Finnhub. Analysts are expecting revenue ...

Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral ...

Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $3.41 per share versus the Zacks Consensus Estimate of a loss of $1.91. This compares to loss of $5.50 per share a year ago. These ...

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biotechnology ...